Company Filing History:
Years Active: 2017
Title: John Biggerstaff: Innovator in Cancer Therapeutics
Introduction
John Biggerstaff is a notable inventor based in Oak Ridge, TN (US). He has made significant contributions to the field of cancer therapeutics through his innovative research and patent work. His dedication to advancing medical science is evident in his patented inventions.
Latest Patents
John Biggerstaff holds a patent for "Soluble fibrin inhibitory peptides and uses thereof." This invention demonstrates that soluble fibrin binds to both Mac-1 and ICAM-1-expressing cells, inhibiting adherence of these cells and immune cytotoxicity, thus inducing immune suppression in cancer. Additionally, the invention shows that soluble fibrin enhances metastasis in an in vivo model. The utility of specific peptides that block the binding of soluble fibrin to these cells as therapeutic agents in cancer progression and metastasis is also highlighted. Furthermore, these peptides may be used to treat other diseases such as cardiovascular disease, arthritis, and various inflammatory responses where there are increased levels of soluble fibrin.
Career Highlights
John is currently associated with Ension Inc., where he continues to work on innovative solutions in the medical field. His research has the potential to change the landscape of cancer treatment and improve patient outcomes.
Collaborations
John collaborates with Brandy Weidow, contributing to the advancement of their shared goals in medical research and innovation.
Conclusion
John Biggerstaff's work exemplifies the impact of innovation in the medical field, particularly in cancer therapeutics. His patented inventions and ongoing research hold promise for future advancements in treatment options.